Press Releases

Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week (DDW)

Panbela Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025

Trial’s lower-than-expected event rate suggests improved survival outcomes

Panbela Announces Poster Presentation at American Association for Cancer Research

Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models

Panbela Announces Transfer to OTCQB Market

Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results

Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on 3/26/24

Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements

Panbela Announces Closing of Approximately $9.0 Million Public Offering

Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)

Panbela Announces Pricing of Approximately $9.0 Million Public Offering